Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+0,47%
1 067,36
+4,96
+0,47%
—1 062,401 064,141 071,991 061,02——
SIXC
Communications
SIXC
Communications
SIXC
-0,54%
603,48
-3,26
-0,54%
—606,74606,74609,84602,33——
SIXE
Energy
SIXE
Energy
SIXE
+0,54%
1 244,93
+6,72
+0,54%
—1 238,211 236,601 247,741 232,10——
SIXI
Industrials
SIXI
Industrials
SIXI
+0,68%
1 730,38
+11,77
+0,68%
—1 718,611 723,231 741,481 717,47——
SIXM
Financials
SIXM
Financials
SIXM
+0,33%
639,47
+2,10
+0,33%
—637,37638,27642,30638,27——
SIXR
Staples
SIXR
Staples
SIXR
+0,16%
854,95
+1,36
+0,16%
—853,59854,05858,19851,34——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+0,11%
218,56
+0,23
+0,11%
—218,33218,33219,73217,15——
SIXT
Technology
SIXT
Technology
SIXT
+1,02%
3 631,59
+36,78
+1,02%
—3 594,813 620,103 657,473 615,34——
SIXU
Utilities
SIXU
Utilities
SIXU
+0,80%
915,77
+7,23
+0,80%
—908,54909,50917,35907,07——
SIXV
Health care
SIXV
Health care
SIXV
+1,19%
1 512,81
+17,81
+1,19%
—1 495,001 499,611 517,101 499,61——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,41%
2 408,21
+9,90
+0,41%
—2 398,312 406,822 421,802 404,22——
AGIO:NASDAQ
Agios Pharmaceuticals Inc
28,14 $
-2,26%
(-0,65) 1D
28,14 $
0,00% (0,00)
After hours
Closed: 22 մյս, 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AGIO...
Open
28,69 $
High
29,10 $
Low
28,04 $
Mkt. cap
1,67 մլրդ
Avg. vol.
1,12 մլն
Volume
874,52 հզր
52-wk high
45,99 $
52-wk low
22,24 $
EPS
-7,25 $
Beta
0,58
Shares outstanding
59,47 մլն
No. of employees
540
News stories
From sources across the web
Profile
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
About Agios Pharmaceuticals Inc
CEO-
Employees540
Founded2008
Headquarters-
Sector-
Websiteagios.com
Last report
29 ապր, 2026 թ.
Fiscal period
Q1 2026
EPS / Est. (USD)
-1,69 $ / -1,79 $
+5,66%beat
Revenue / Est. (USD)
20,75 մլն / 13,34 մլն
+55,57%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
2025 թ. հնս
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
Revenue
12,46 մլն
12,88 մլն
19,97 մլն
20,75 մլն
Cost of goods sold
93,64 մլն
88,48 մլն
89,94 մլն
82,47 մլն
Cost of revenue
93,64 մլն
88,48 մլն
89,94 մլն
82,47 մլն
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
45,87 մլն
41,27 մլն
51,61 մլն
48,30 մլն
Operating expense
45,87 մլն
41,27 մլն
51,61 մլն
48,30 մլն
Total operating expenses
139,51 մլն
129,75 մլն
141,54 մլն
130,77 մլն
Operating income
-127,06 մլն
-116,87 մլն
-121,58 մլն
-110,02 մլն
Other non operating income
523,00 հզր
67,00 հզր
113,00 հզր
119,00 հզր
EBT including unusual items
-112,02 մլն
-103,43 մլն
-109,06 մլն
-99,11 մլն
EBT excluding unusual items
-112,02 մլն
-103,43 մլն
-109,06 մլն
-99,11 մլն
Income tax expense
-
-
-1,02 մլն
-
Effective tax rate
-
-
0,93%
-
Other operating expenses
-
-
-
-
Net income
-112,02 մլն
-103,43 մլն
-108,04 մլն
-99,11 մլն
Net profit margin
-899,40%
-803,05%
-541,09%
-477,74%
Earnings per share
-1,93
-1,78
-1,85
-1,69
Interest and investment income
14,51 մլն
13,37 մլն
12,41 մլն
10,80 մլն
Interest expense
-
-
-
-
Net interest expenses
14,51 մլն
13,37 մլն
12,41 մլն
10,80 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
-125,80 մլն
-115,50 մլն
-120,31 մլն
-108,66 մլն
Gain or loss from assets sale
5,00 հզր
299,00 հզր
-299,00 հզր
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer